Pneumagen: out-competing viral sugar binding to prevent infection
Pneumagen targeting infections, cancer by co-opting and enhancing microbial carbohydrate binders
With its platform of carbohydrate-binding proteins, Pneumagen is co-opting a pathogenic tool for interacting with host cells to block infections and adapting the technology for use against cancer.
Both viruses and bacteria can interact with human cells via proteins that recognize sugar residues, including sialic acid, on proteoglycans.
However, the overwhelming majority of industry programs targeting the interaction have focused on viral infections, and most use small molecules to inhibit viral glycosidases, which upon mutation could render the virus drug-resistant.
Scotland-based Pneumagen Ltd., which emerged from stealth in